Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...
It's time for researchers to reconsider the current paradigm of cancer as a genetic disease, argued Sui Huang from the Institute for Systems Biology, USA, and colleagues in a new essay published March ...
Scientists have made a potentially “life-changing” discovery that could pave the way for new drugs to treat Parkinson’s ...
Autoimmune diseases, which are estimated to affect more than 15 million people in the U.S., occur when the body responds to immune-system false alarms, and infection-fighting first responders are sent ...
Bird experts agree Creamsicle is rare — and potentially even unique — in its colouring. But they disagree about what’s ...
The Black Wall Street Times on MSN14h
Sickle cell treatment that "cured" New York patient costs millionsSebastien Beauzile’s recently announced cure from sickle cell disease brings hope to thousands of mostly Black Americans who ...
The rare mutation was spotted in the infamous death adder - one of the most venomous land snakes in the world - during a ...
Sarepta Therapeutics Inc.'s stock tumbled 23% on Tuesday after the biotech said a patient who used its gene therapy Elevidys for the rare disease Duchenne muscular dystrophy has died of acute liver ...
Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP -- -- High ...
Prime Medicine's program leverages the Company's universal liver lipid nanoparticle (LNP) to edit the E342K (Pi*Z) mutation in the SERPINA1 gene, the prevalent disease-causing mutation in AATD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback